Idaho is telling health insurers to prepare for new enhanced breast cancer screening law
Reps. John Shirts, left, Jaron Crane and Brooke Green share a smile as legislators shave their heads March 25, 2025, to support Green's battle against breast cancer. (Clark Corbin/Idaho Capital Sun)
Months before a new Idaho law will require health insurance companies to expand breast cancer screening coverage, the Idaho Department of Insurance is guiding insurers on how to prepare.
The Idaho Legislature widely approved the new law through House Bill 134 this year. But the law doesn't take effect until Jan. 1, 2026.
The new law will require health insurance companies to cover supplemental breast cancer screening when abnormalities aren't found or suspected in the breast of people who are at high risk.
'Early detection saves lives, and I'm thrilled to have helped pass this impactful legislation that will make life-saving care more affordable and accessible for so many Idaho women at high risk for breast cancer,' Rep. Brooke Green, a Boise Democrat who sponsored the bipartisan-backed legislation while she battles breast cancer, said in a written statement.
Days after her first breast cancer diagnosis, Green's radiologist brought the issue to her attention, she previously told the Sun. In a show of solidarity, several Idaho lawmakers shaved their heads in late March, as Green prepared to start chemotherapy.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Under the bill, people will be considered at high risk for breast cancer due to personal or family history, genetic predisposition or other factors. Supplemental breast cancer screening required to be covered by the bill includes magnetic resonance imaging, or an MRI.
Idaho legislators shave heads to support colleague, raise awareness for breast cancer screening
According to a news release last week by the Idaho Department of Insurance, the new law requires health insurance plans cover 'all costs associated with one supplemental breast cancer screening every year' for people covered by their health insurance plans who have a high risk of breast cancer.
Here's how that will work:
That screening 'must be covered with no patient cost-sharing,' which includes deductibles, copayments or coinsurance, if it is provided by in-network health care providers, the Idaho Department of Insurance says.
Additional costs can be charged for services from out-of-network providers.
For other breast imaging services that go beyond the new law's minimum service requirements, such as diagnostic imaging or supplemental screenings conducted more than once a year, the health insurance plan's patient cost-sharing rules can apply, the insurance department says.
Idaho health insurance companies must update their plan documents and notify members about the new benefits, according to new guidance to insurers from the Idaho Department of Insurance.
'Consumers should contact their insurer with any questions, or contact our department if they experience coverage issues,' Idaho Department of Insurance Market Oversight Bureau Chief Shannon Hohl said in a written statement. 'Our consumer affairs team is available to help with insurance questions and concerns.'
In a written statement, Idaho Department of Insurance Director Dean Cameron thanked the Legislature and several lawmakers for supporting the bill, saying it will 'help Idahoans access the critical preventive services they need.'
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
6 hours ago
- Medscape
MRI-Led Surveillance Stratifies Prostate Cancer Risk
In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation. METHODOLOGY: Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans. Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visible lesions at baseline. Patients were stratified into four groups on the basis of baseline risk factors, including GS (3 + 3 vs 3 + 4) and MRI visibility ("non-visible disease" vs "visible disease"). The primary outcome was event-free survival, with an event defined as the detection of GS ≥ 4 + 3 or the initiation of any prostate cancer treatment. The median follow-up duration was 64 months per person overall and 72 months for 732 patients without an event. At baseline, 64% of patients had GS 3 + 3 and 36% had GS 3 + 4; 49% of those with GS 3 + 4 had MRI-visible disease. TAKEAWAY: Event-free survival rates varied significantly on the basis of the risk group, with 5-year rates of 91% for non-visible GS 3 + 3, 71% for MRI-visible GS 3 + 3, 71% for non-visible GS 3 + 4, and 44% for MRI-visible GS 3 + 4 disease. Among 487 patients who underwent follow-up biopsies, histological upgrade to GS ≥ 4 + 3 occurred in 67 patients; non-visible GS 3 + 3 cases had 5- and 10-year rates of 1.2% and 6.1%, respectively, for histological progression to GS ≥ 4 + 3, while the rates were 17% and 43% for those with MRI-visible GS 3 + 4 disease at baseline, respectively. Progression to nodal or bone metastases was observed in 10 patients, occurring only in those who had declined recommended follow-up MRI and/or biopsies. The 10-year rate of commencing treatment was 28% for those with non-visible GS 3 + 3 disease vs 85% for those with MRI-visible GS 3 + 4 disease and 46% for those with non-visible GS 3 + 4 disease vs 54% for those with MRI-visible GS 3 + 3 disease. IN PRACTICE: "Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes. Prospective, multicentre, clinical trials are required and currently being designed to further evaluate this approach," the authors wrote. SOURCE: This study was led by Cameron Englman, Division of Surgery & Interventional Science, University College London, London, England. It was published online on May 27, 2025, in European Urology . LIMITATIONS: Compared with time-based biopsy protocols, the MRI-led risk-adapted approach may underestimate histological progression. Additionally, as a cohort study without a strict protocol, practice evolved alongside contemporary pathology and radiology standards, with MRI quality, reporting standards, and the definition of radiological progression varying over time, particularly improving after the adoption of the PRECISE recommendations in 2016. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving consulting fees and grants and having other ties with various sources.


Medscape
7 hours ago
- Medscape
Radiology Workforce Shortages Impacting Cancer Care
A chronic shortage of radiologists and oncologists is putting patients in the UK at risk, a new report found. The annual workforce census by the Royal College of Radiologists (RCR) warned that the safe delivery of NHS cancer care is becoming 'increasingly impossible' due to an escalating shortfall of doctors coupled with rising demand for care. In 2024, the UK had a 29% shortfall of clinical radiologists, with regional gaps ranging from 25% in Scotland to 32% in Wales. The workforce grew by 4.7% that year — less than in 2023, when it increased by 6.3%. The college forecasts the radiologist shortfall will reach 39% by 2029. Oncology Under Strain Clinical oncologists are also in short supply, with a current 15% gap expected to rise to 19% by 2029. This is despite a 5.4% increase in the workforce in 2024—the strongest growth since 2018. The RCR reported that 23% of cancer centres were experiencing recruitment freezes, making it harder to meet growing demand. Demand Continues to Outpace Capacity The shortages threaten the government's plans to cut waiting times and improve cancer outcomes. In 2024, demand for computerised tomography (CT) and magnetic resonance imaging (MRI) grew by 8%, but workforce growth did not keep pace. Every radiology leader surveyed last year reported delays to diagnostic scans caused by staff shortages. Nine in 10 radiology team leaders reported that patients were waiting longer to start treatment, while seven in 10 expressed concern that staff shortages were putting patient safety at risk – down slightly from 85% in 2023. Chronic problems such as workforce shortages, reporting backlogs, and staff vacancies remain too high, according to Dr Robin Proctor, the RCR's m edical director responsible for professional practice and clinical radiology. Consultants Leaving Earlier Staff retention is worsening, with experienced consultants leaving the NHS at younger ages. In 2024, the median age of consultant clinical radiologists leaving the NHS workforce was 50 – down from 56 in 2020. Four in five (79%) of leavers were under 60, and two in five (42%) were under 45. Clinical oncologists followed a similar trend. Their median exit age dropped to 54, from 57 in 2023 and 59 in 2022. Nearly 76% of leavers were under 60, and 26% were under 45. One consultant clinical oncologist told the college that delays in scans and treatment were resulting in missed or late cancer diagnoses. Some patients' conditions were deteriorating or reaching a stage where treatment was no longer possible. Changing Work Practices 'Working conditions and ways of working need to change if we are to address this problem and meet the growing demand for our expertise,' Proctor said. The RCR has called on the government to invest in training and recruitment. In 2024, the NHS spent an estimated £325 million on temporary radiology staff. The cost of outsourcing had doubled since before the COVID-19 pandemic and had surged by almost a quarter in the past year. The RCR estimated that increasing radiology trainee numbers by 50% could eliminate three-quarters of the current shortfall and save the NHS £460 million over the next 10 years. 'Patients are being failed by a chronic lack of radiologists and oncologists,' said RCR president Dr Katharine Halliday. 'The longer we delay action, the worse it gets,' she added.
Yahoo
16 hours ago
- Yahoo
Lowcountry doctor believes Lindsey Graham is ‘beatable' in SC Senate race
CHARLESTON, S.C. (WSAV) – A Lowcountry doctor said the time to stay on the sidelines is over. Now she is making a second run at a South Carolina political office. Dr. Annie Andrews has officially announced her candidacy for South Carolina Senate. She will run as a Democrat for the seat currently held by Lindsey Graham. Andrews, a Charleston Pediatrician, made an unsuccessful run for the SC District 1 Congressional seat in 2022. Since that race she has stayed active, gaining a strong presence as an advocate on social media. Because of the state of the nation it was time to get off the web and into the race. 'Everything that I've seen happen since the inauguration in 2020 helps me understand how necessary it is for voices like mine to step up and to take on these fights,' Andrews said. 'As a physician, I'm watching this coordinated attack on our nation's health care system and our nation's public health infrastructure. With the elevation of a conspiracy theorist to the secretary of the Department of Health and Human Services, we're seeing this coordinated attack gutting our nation's Medicaid program, which is the largest insurer for children in South Carolina.' A dedicated pediatrician and public health expert, Andrews talks about her career career on the frontlines-treating kids with gunshot wounds, kids whose families can't afford insulin or even their next meal, and kids in mental health crises with nowhere to turn. She called what's going on in Washington 'corruption and BS', hurting real families, and that our kids are paying the price. 'It is infuriating because I know that Lindsey Graham doesn't really actually care about the Medicaid program or the SNAP program,' Andrews said. 'But he's willing to cut them for the sole purpose of delivering tax cuts to billionaires because he's a corrupt career politician who has lost his way and lost touch with the people of South Carolina.' It is the people of South Carolina that Andrews wants to hear from and serve if elected. 'He (Graham) boldly said into a microphone not that long ago that he doesn't need a town hall because he's in Washington, D.C. to do what Donald Trump tells him to do.' Andrews said. 'Well, that's not the job of a U.S. Senator. You know, I believe in the kids and families in South Carolina. I believe in South Carolina. And I'm not afraid to stand up to people like Lindsey Graham who are willing to sell them out.' That 'sell out' starts with the latest Trump budget proposal. 'This bill that he is so eager to vote yes on will kick 1.1 million South Carolinians off of the Medicaid program,' Andrews said. 'Our hospitals cannot sustain a budget impact like that. This will impact every single person in the state, whether you are on the Medicaid program or not. And it is cruel and devastating. And I can't sit on the sidelines while our elected senator is willing to go along with this plan.' While Andrews knows it's a tall task to take out Graham, an incumbent who has been in office since 2002, recent elections in the state, and the reaction of the people she has spoken to, give her hope. 'South Carolina, House District 50. That's a district that Kamala carried by five points and the Democrat won it by 42 points,' Andrews details. 'That's a 37-point swing, which tells you that everything is in play. And we cannot count out Democrats just because we're in a red state. Republicans and Democrats alike are fed up with the chaos from this administration because of career corrupt politicians like Lindsey Graham. I wouldn't be in this race if I didn't think it was winnable. He's as vulnerable as he ever has been because he says he's as corrupt as he ever has, he ever has been, and someone needs to run against him, and I am prepared to do that. And I will bring home a victory in November 2026 if people give this campaign a chance.' Andrews is one of four Democratic candidates announced so far. Graham has two challengers who have already signed on to run against him in the Republican primary. Dr. Annie Andrews for Senate Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.